Published Online: May 20, 2012. doi:10.1001/jama.2012.5521
Author Contributions: Dr Bach had full access to all of the data in
the study and takes responsibility for the integrity of the data and the accuracy of the data
Study concept and design: Bach, Mirkin, Azzoli, Berry, Brawley,
Byers, Colditz, Gould, Smith-Bindman, Wood, Qaseem, Detterbeck.
Acquisition of data: Bach, Mirkin, Oliver, Detterbeck.
Analysis and interpretation of data: Bach, Mirkin, Oliver, Azzoli,
Berry, Brawley, Byers, Colditz, Gould, Jett, Sabichi, Smith-Bindman, Wood, Qaseem,
Drafting of the manuscript: Bach, Mirkin, Oliver, Azzoli, Berry,
Brawley, Byers, Colditz, Jett, Sabichi, Smith-Bindman, Qaseem, Detterbeck.
Critical revision of the manuscript for important intellectual
content: Bach, Mirkin, Azzoli, Berry, Brawley, Byers, Colditz, Gould, Sabichi, Smith-Bindman,
Wood, Qaseem, Detterbeck.
Statistical analysis: Oliver, Berry, Colditz, Gould, Smith-Bindman,
Administrative, technical, or material support: Bach, Mirkin, Oliver,
Brawley, Byers, Colditz.
Study supervision: Bach, Azzoli, Detterbeck.
Conflict of Interest Disclosures: All authors have completed and
submitted the ICJME form for Disclosure of Potential Conflicts of Interest. Dr Bach reported that he
has received speaking fees from Genentech. Dr Berry reported that he is co-owner of Berry
Consultants LLC, which designs adaptive clinical trials for pharmaceutical companies, medical device
companies, and National Institutes of Health cooperative groups. To the best of his knowledge, none
of these parties have any interest in lung cancer screening. Dr Gould reported that he receives
grant support from the National Cancer Institute. Dr Jett reported that he has grants pending for
work related to screening and early detection of lung cancer with Oncimmune and Isense. Dr Sabichi
reported being a member of the National Cancer Institute's PDQ Prevention and Screening Editorial
Board and possessing a pending patent for a test for the detection of bladder cancer. Dr Wood
reported his participation in the development of the National Comprehensive Cancer Network (NCCN)
clinical practice guidelines for lung cancer screening in his role as Chair of the NCCN Lung Cancer
Screening Panel. Dr Detterbeck reported that he was reimbursed for travel costs associated with his
work on the Oncimmune advisory board and has participated without compensation in a symposium on CT
screening sponsored by Covidien. No other conflicts were reported.
Role of the Sponsors: The American College of Chest Physicians,
American Cancer Society, American Society of Clinical Oncology, and National Comprehensive Cancer
Network all reviewed and approved the manuscript but did not have a role in the design and conduct
of the study; in the collection, management, analysis, and interpretation of the data; or in the
preparation of the manuscript.
Members of the panel had the following roles: Dr Bach (project lead),
Mr Mirkin (project coordinator). Evidence subcommittee: Dr Berry, Dr Colditz, Dr Gould (chair), and
Dr Smith-Bindman. Writing subcommittee: Dr Azzoli, Dr Brawley, Dr Byers (co-chair), Dr Jett, Maryann
Napoli, Dr Sabichi, Dr Wood, Dr Qaseem, and Dr Detterbeck (co-chair)
Additional Contributions: We are grateful for the assistance of
Geoffrey Schnorr, BS (MSKCC), who provided administrative, editorial, and research assistance, as
well as Sandra Zelman Lewis, PhD (ACCP), Mark Somerfield, PhD (ASCO), Jerry Seidenfeld, PhD (ASCO),
Joan McClure, MS (NCCN), and Kate O’Toole, MBA (ACS), who provided administrative assistance.
These individuals are employed by their respective organizations but did not receive any
compensation specific to this project.
This artticle was corrected for errors on April 22, 2013.